Welcome to our dedicated page for Galecto news (Ticker: GLTO), a resource for investors and traders seeking the latest updates and insights on Galecto stock.
Galecto, Inc. (NASDAQ: GLTO) is a clinical-stage biopharmaceutical company developing novel therapies for cancer and liver diseases, with a growing focus on hematological malignancies. The GLTO news feed on Stock Titan aggregates company announcements, scientific updates and regulatory disclosures so readers can follow how Galecto’s pipeline and corporate strategy evolve over time.
Recent news emphasizes Galecto’s shift toward blood cancers, highlighted by the acquisition of Damora Therapeutics and the integration of a mutant calreticulin (mutCALR)-driven myeloproliferative neoplasm portfolio. Updates describe progress on DMR-001, an anti-mutCALR monoclonal antibody for essential thrombocythemia and myelofibrosis, and DMR-002, an additional anti-mutCALR antibody. News items also cover GB3226, a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of acute myeloid leukemia, including preclinical data presentations and plans for first-in-human studies.
Investors and followers of GLTO can use this page to track a range of developments: pipeline milestones such as planned IND submissions, preclinical and early clinical data disclosures, corporate transactions including the Damora acquisition and private placements, and leadership changes like the appointment of new executives with hematology/oncology experience. Financial result releases offer context on Galecto’s operating expenses, research and development priorities and cash runway.
This news archive is useful for anyone monitoring how Galecto executes on its strategy in hematology-oncology and liver disease, from the advancement of DMR-001 and GB3226 to the progress of GB1211 in liver cirrhosis and oncology combinations. Bookmark this GLTO news page to quickly access the latest company press releases and related updates as they are reported.
Galecto, Inc. (GLTO) will host a KOL webinar on June 9, 2021, at 8am ET, focusing on the treatment landscape for myelofibrosis. The event will feature Dr. Srdan Verstovsek, who will discuss current treatments and opportunities for Galecto's GB2064, an oral LOXL2 inhibitor targeted at myelofibrosis. Galecto’s President will also provide updates on development status. As myelofibrosis treatments face limitations, GB2064 represents a potential advance. Registration details for the webinar can be found on their website.
Galecto, Inc. (NASDAQ: GLTO) has appointed Garrett Winslow as Senior Vice President and General Counsel. Winslow, with over 15 years of experience in the life sciences sector, will oversee legal, compliance, and enterprise risk management, reporting directly to CEO Hans Schambye. Previously, he was General Counsel at Spring Bank Pharmaceuticals and a partner at Mintz. His expertise is expected to strengthen Galecto's clinical development pipeline. The company is focused on developing novel therapies for fibrosis and cancer, with clinical programs advancing in 2021.
Galecto, Inc. (NASDAQ: GLTO) will host a key opinion leader event on June 9, 2021, to address the treatment landscape and unmet needs in myelofibrosis. The event will feature discussions on GB2064, a LOXL2 inhibitor entering phase 2 trials. Prior to this, executives will participate in investor conferences, including the Bank of America Securities Virtual Healthcare Conference on May 12 and Jefferies Virtual Healthcare Conference on June 3. Live webcasts of these events will be available on Galecto's website.
Galecto, Inc. (NASDAQ: GLTO) reported Q1 2021 financial results, highlighting a net loss of $13.3 million, or $(0.53) per share, compared to $5.7 million, or $(21.83) per share, in Q1 2020. The company is advancing its pipeline with plans for three Phase 2 clinical trials, namely MYLOX-1 for myelofibrosis, GALLANT-1 for non-small cell lung cancer, and GULLIVER-2 for liver cirrhosis. As of March 31, 2021, Galecto had $149 million in cash, expected to fund operations into 2024. R&D expenses rose to $10 million from $4.7 million due to increased clinical spending.
Galecto announced a publication in the Gastric Cancer journal highlighting the role of galectin-3 in gastric cancer progression. The study suggests that high levels of galectin-3 correlate with poor prognosis in patients. The preclinical research indicates that GB1107, a galectin-3 inhibitor, effectively inhibits tumor growth in mouse models. The company plans to initiate clinical studies for GB1211, another galectin-3 inhibitor, targeting Non-Small-Cell Lung Cancer and other cancer types.
Galecto, Inc. (GLTO) reported its 2020 operating and financial results, highlighting a successful IPO raising $160 million. Cash reserves stood at approximately $164 million, expected to fund operations into 2024. R&D expenses rose to $24.6 million, driven by the GALACTIC-1 study. The net loss decreased to $34.8 million, or $(7.62) per share, improving from $(161.82) in 2019. Galecto aims to initiate three Phase 2 trials in 2021 and continues to advance the GALACTIC-1 trial in Idiopathic Pulmonary Fibrosis (IPF) to address unmet treatment needs.
Galecto, Inc. (NASDAQ: GLTO) announced a webinar on March 30, 2021, at 2 PM ET, discussing the treatment landscape for idiopathic pulmonary fibrosis (IPF) and the potential of GB0139. Key Opinion Leader Toby Maher, MD, will present insights on unmet patient needs and recent biomarker data for GB0139, an inhalable treatment for IPF currently in phase 2b trials. CEO Hans Schambye will update on GB0139's progress, with a Q&A session featuring key medical officers. The session will be archived for 30 days for later viewing.
Galecto, Inc. (NASDAQ: GLTO) has announced an expert panel webinar focusing on idiopathic pulmonary fibrosis (IPF) treatment on March 30, 2021. Renowned KOL Toby Maher, MD, will discuss unmet needs in IPF treatments and share promising biomarker data on Galecto's inhalable treatment, GB0139, which is in a phase 2b trial. CEO Hans Schambye will also provide updates on GB0139’s trial modifications. The session aims to address the evolving treatment landscape for IPF, enhancing patient care understanding. Registration is available online.
Galecto, Inc. (NASDAQ: GLTO) announced that the independent Data Safety Monitoring Board (DSMB) recommended discontinuing the 10 mg dosing arm and combination treatments in its Phase 2b GALACTIC-1 study of GB0139 for Idiopathic Pulmonary Fibrosis (IPF). However, patient enrollment in the 3 mg arm without concurrent treatments will continue. The DSMB noted an imbalance in serious adverse experiences but no mortality differences. Galecto plans additional trials this year and anticipates initial data from GALACTIC-1 in 2022.
BOSTON, Feb. 09, 2021 – Galecto, Inc. (NASDAQ: GLTO) announced that CEO Hans Schambye will participate in several upcoming investor conferences. Events include the SVB Leerink 10th Annual Global Healthcare Conference on February 24, the Credit Suisse London Global Healthcare Conference from March 2-4, and the Oppenheimer 31st Annual Healthcare Conference on March 16. Both Schambye and CFO Jon Freve will be available for one-on-one meetings with investors. Presentations will be webcasted, and recordings will be accessible for 30 days post-event.